Meta-analysis · people
Ecnoglutide lowered HbA1c and weight in type 2 diabetes: meta-analysis
Checked against the paper Meta-analysisPublished by PepVault
The takeaway
In pooled trials of adults with type 2 diabetes, ecnoglutide lowered blood sugar and weight versus controls, with more side effects that were mostly mild gut symptoms and no significant rise in serious ones.
- Kind
- Meta-analysis
- Studied in
- People
- Number studied
- 1643
- Published
- 2026
- Journal
- Endocrinol Diabetes Metab
What they tested
The team wanted to know how well ecnoglutide works and how safe it is for adults with type 2 diabetes when the randomized trials are pooled together.
How the study was done
A systematic review and meta-analysis that pooled a small set of randomized controlled trials with 1643 adults with type 2 diabetes. The trials compared ecnoglutide (1162 people) with placebo, a dummy treatment, or another active drug (444 people).

Model. Individual results vary.
What they found
Compared with control groups, ecnoglutide lowered HbA1c, a long-term average of blood sugar, with a mean difference of -0.44 (95% CI -0.55 to -0.33). Body weight fell with a mean difference of -5.63 (95% CI -7.90 to -3.35), and fasting blood sugar fell with a mean difference of -0.81 (95% CI -1.03 to -0.59). Insulin sensitivity, blood fats and liver enzymes also improved. Side effects were more common with ecnoglutide (risk ratio 1.09), mostly gut-related and mild to moderate, and serious side effects did not differ significantly between groups.
What it doesn’t show
The analysis pools only a handful of trials and mixes placebo and active-drug comparisons, so it can't say how ecnoglutide compares with any single drug. It covers adults with type 2 diabetes only, not people with obesity who don't have diabetes.
The paper
Kumar et al. Comparative Efficacy and Safety of Ecnoglutide in Type 2 Diabetes: A Systematic Review and Meta-Analysis. Endocrinol Diabetes Metab. 2026.
The compound
More studies on Ecnoglutide
- Ecnoglutide: HbA1c fell up to 2.43% at 24 weeks in EECOH-1Randomized trial · people · 2026
- Ecnoglutide: HbA1c fell up to 1.91% vs 1.65% with dulaglutideRandomized trial · people · 2025
- Ecnoglutide: 13.2% weight loss at 40 weeks in the 2.4 mg armRandomized trial · people · 2025
- Ecnoglutide: HbA1c fell up to 2.39% at 20 weeks in type 2 diabetesRandomized trial · people · 2024
- Ecnoglutide: well tolerated weekly for 6 weeks in a phase 1 trialRandomized trial · people · 2023
- Every study on Ecnoglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.